SCHEMBL29394083

SCHEMBL29394083

c1ccc(-c2ccncn2)nc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.67
LMNA P02545 3/20 0.67
CCR1 P32246 3/20 0.67
CCR5 P51681 3/20 0.67
CCR8 P51685 3/20 0.67
METAP1 P53582 2/20 0.67
CYP1A2 P05177 1/20 0.67
POLB P06746 1/20 0.67
BLM P54132 1/20 0.67
HIF1A Q16665 1/20 0.67
DOHH Q9BU89 1/20 0.67
P4HTM Q9NXG6 1/20 0.67
NPC1 O15118 6/20 0.56
RAB9A P51151 5/20 0.56
TP53 P04637 4/20 0.56
ALOX15 P16050 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
HTT P42858 2/20 0.56
TDP1 Q9NUW8 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4294864 1.00 KDM4E (0.67) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL27634628 0.85 KDM4E (0.74) KDM4ELMNACCR1CCR5CCR8
SCHEMBL10402322 0.85 HSP90AA1 (0.48) KDM4ELMNACCR1CCR5CCR8
SCHEMBL30595872 0.84 HSP90AA1 (0.52) KDM4ELMNACCR1CCR5CCR8
SCHEMBL2814353 0.84 HSP90AA1 (0.52) KDM4ELMNACCR1CCR5CCR8
SCHEMBL1181563 0.82 KDM4E (0.88) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL29351528 0.82 KDM4E (1.00) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL29907716 0.82 KDM4E (1.00) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL3711450 0.82 KDM4E (1.00) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL5922 0.82 KDM4E (1.00) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415795-B2 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators NXERA PHARMA UK LIMITED (GB) 2025-09-16 US disclosed
US-20240092754-A1 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS NXERA PHARMA UK LIMITED (GB) 2024-03-21 US disclosed
US-20220056009-A1 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS NXERA PHARMA UK LIMITED (GB) 2022-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415795-B2 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators GRM5, GRM6, GRM2 KDM4E 1352/4885LMNA 4632/4885CCR1 806/4885
US-20240092754-A1 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS GRM5, GRM6, GRM2 KDM4E 1352/4885LMNA 4632/4885CCR1 806/4885
US-20220056009-A1 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS GRM5, GRM6, GRM2 KDM4E 1352/4885LMNA 4632/4885CCR1 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.